Skip to content


Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.
Trade Name Crysvita
Common Name Burosumab
Indication familial hypophosphatemia, familial hypophosphatemic rickets
Drug Class Monoclonal antibodies: fully human, bone target
Get full access now